Your browser doesn't support javascript.
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
Bajema, Kristina L; Wiegand, Ryan E; Cuffe, Kendra; Patel, Sadhna V; Iachan, Ronaldo; Lim, Travis; Lee, Adam; Moyse, Davia; Havers, Fiona P; Harding, Lee; Fry, Alicia M; Hall, Aron J; Martin, Kelly; Biel, Marjorie; Deng, Yangyang; Meyer, William A; Mathur, Mohit; Kyle, Tonja; Gundlapalli, Adi V; Thornburg, Natalie J; Petersen, Lyle R; Edens, Chris.
  • Bajema KL; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Wiegand RE; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Cuffe K; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Patel SV; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Iachan R; ICF Inc, Fairfax, Virginia.
  • Lim T; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Lee A; ICF Inc, Fairfax, Virginia.
  • Moyse D; ICF Inc, Fairfax, Virginia.
  • Havers FP; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Harding L; ICF Inc, Fairfax, Virginia.
  • Fry AM; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Hall AJ; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Martin K; ICF Inc, Fairfax, Virginia.
  • Biel M; ICF Inc, Fairfax, Virginia.
  • Deng Y; ICF Inc, Fairfax, Virginia.
  • Meyer WA; Quest Diagnostics, Secaucus, New Jersey.
  • Mathur M; BioReference Laboratories, Elmwood Park, New Jersey.
  • Kyle T; ICF Inc, Fairfax, Virginia.
  • Gundlapalli AV; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Thornburg NJ; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Petersen LR; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Edens C; COVID-19 Response, US Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA Intern Med ; 181(4): 450-460, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-965464
Semantic information from SemMedBD (by NLM)
1. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
2. Antibodies PART_OF Persons
Subject
Antibodies
Predicate
PART_OF
Object
Persons
3. 65 years PROCESS_OF Persons
Subject
65 years
Predicate
PROCESS_OF
Object
Persons
4. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
5. Antibodies PART_OF Persons
Subject
Antibodies
Predicate
PART_OF
Object
Persons
6. 65 years PROCESS_OF Persons
Subject
65 years
Predicate
PROCESS_OF
Object
Persons
ABSTRACT
Importance Case-based surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimates the true prevalence of infections. Large-scale seroprevalence surveys can better estimate infection across many geographic regions.

Objective:

To estimate the prevalence of persons with SARS-CoV-2 antibodies using residual sera from commercial laboratories across the US and assess changes over time. Design, Setting, and

Participants:

This repeated, cross-sectional study conducted across all 50 states, the District of Columbia, and Puerto Rico used a convenience sample of residual serum specimens provided by persons of all ages that were originally submitted for routine screening or clinical management from 2 private clinical commercial laboratories. Samples were obtained during 4 collection periods July 27 to August 13, August 10 to August 27, August 24 to September 10, and September 7 to September 24, 2020. Exposures Infection with SARS-CoV-2. Main Outcomes and

Measures:

The proportion of persons previously infected with SARS-CoV-2 as measured by the presence of antibodies to SARS-CoV-2 by 1 of 3 chemiluminescent immunoassays. Iterative poststratification was used to adjust seroprevalence estimates to the demographic profile and urbanicity of each jurisdiction. Seroprevalence was estimated by jurisdiction, sex, age group (0-17, 18-49, 50-64, and ≥65 years), and metropolitan/nonmetropolitan status.

Results:

Of 177 919 serum samples tested, 103 771 (58.3%) were from women, 26 716 (15.0%) from persons 17 years or younger, 47 513 (26.7%) from persons 65 years or older, and 26 290 (14.8%) from individuals living in nonmetropolitan areas. Jurisdiction-level seroprevalence over 4 collection periods ranged from less than 1% to 23%. In 42 of 49 jurisdictions with sufficient samples to estimate seroprevalence across all periods, fewer than 10% of people had detectable SARS-CoV-2 antibodies. Seroprevalence estimates varied between sexes, across age groups, and between metropolitan/nonmetropolitan areas. Changes from period 1 to 4 were less than 7 percentage points in all jurisdictions and varied across sites. Conclusions and Relevance This cross-sectional study found that as of September 2020, most persons in the US did not have serologic evidence of previous SARS-CoV-2 infection, although prevalence varied widely by jurisdiction. Biweekly nationwide testing of commercial clinical laboratory sera can play an important role in helping track the spread of SARS-CoV-2 in the US.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prevalence study / Randomized controlled trials / Risk factors Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: North America Language: English Journal: JAMA Intern Med Year: 2021 Document Type: Article Affiliation country: Jamainternmed.2020.7976

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prevalence study / Randomized controlled trials / Risk factors Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: North America Language: English Journal: JAMA Intern Med Year: 2021 Document Type: Article Affiliation country: Jamainternmed.2020.7976